

IND SAFETY REPORT: INITIAL WRITTEN REPORT

TO: Division of Biologic Oncology Products, Center for Drug Evaluation and Research, FDA
Division of Drug Oncology Products, Center for Drug Evaluation and Research, FDA

FAX: 301-796-9849

FAX: 301-796-9845

1. IND NUMBER 7921, 11460 74019	2. AGENT NAME Bevacizumab (rhuMab VEGF) Sunitinib malate (SU011248 L-malate; Sutent®)	3. DATE July 24, 2009
--	--	---------------------------------

4. SPONSOR
Division of Cancer Treatment and Diagnosis, National Cancer Institute

5. REPORTER=S NAME, TITLE, AND INSTITUTION Helen Chen, MD-Associate Branch Chief for Investigational Therapeutics III, Investigational Drug Branch, CTEP, DCTD, NCI Pamela Harris, MD –Senior Investigator for Investigational Therapeutics I, Investigational Drug Branch, CTEP, DCTD, NCI	6. PHONE NUMBER 301-496-1196
	7. FAX NUMBER 301-402-0428

8. PROTOCOL NUMBER (AE #)
7537 (AE # 1613977)

9. PATIENT IDENTIFICATION 044	10. AGE 69	11. SEX Male
---	----------------------	------------------------

12. DESCRIPTION OF ADVERSE EVENT
The patient is a 69-year-old male with renal cell carcinoma who experienced grade 2 thrombotic microangiopathy while on a phase I study using the investigational agents bevacizumab and sunitinib. He began his first course of treatment on May 1, 2009, and received his last dose of bevacizumab on May 15, 2009 (Cycle 1, Day 15), and his last dose of sunitinib on July 9, 2009 (Cycle 2, Day 28). On July 10, 2009 (Cycle 2, Day 29), the patient presented to the clinic for follow-up. His laboratory report was suggestive of thrombotic microangiopathy although he was clinically well. Additional information has been requested from the investigative site. There is a reasonable possibility that the experience may have been caused by the drugs.

13. DOSE, ROUTE, AND SCHEDULE
Cycle = 42 days
Bevacizumab: 5 mg/kg IV over 90 - 30 minutes on Days 1, 15, and 29
SU11248: 37.5 mg PO once daily on Days 1-28

14. DATES OF TREATMENT
The patient started the investigational therapy on May 15, 2009, and received his last dose of bevacizumab on May 15, 2009 (Cycle 1, Day 15), and sunitinib on July 9, 2009 (Cycle 2, Day 28).

15. ACCRUAL AND IND EXPERIENCE
Number of patients enrolled in NCI-sponsored clinical trials using bevacizumab = 22,615 and using sunitinib = 1958. There has been 1 other case of thrombotic microangiopathy reported to the NCI through AdEERS as serious adverse events for bevacizumab and 7 other cases of thrombotic microangiopathy reported to the NCI through AdEERS as serious adverse events for sunitinib.

16. COMMENTS

AT THIS TIME, NO OTHER INFORMATION IS AVAILABLE. IF UPON FURTHER INVESTIGATION RELEVANT INFORMATION BECOMES AVAILABLE, THEN A FOLLOW-UP REPORT WILL BE SUBMITTED IN ACCORDANCE WITH 21CFR 312.32(d)(2).

DISCLAIMER per 21 CFR 312.32(e): THIS SAFETY REPORT DOES NOT NECESSARILY REFLECT A CONCLUSION OR ADMISSION BY THE CTEP IDB SENIOR INVESTIGATOR/ SPONSOR THAT THE INVESTIGATIONAL AGENT/THERAPY CAUSED OR CONTRIBUTED TO THE ADVERSE EXPERIENCE BEING REPORTED.